Wen-Ming Chen (Wenming Chen)

Publication Activity (10 Years)

Years Active: 2017-2021
Publications (10 Years): 5

Top Topics

Prognostic Factors

Acute Lymphoblastic Leukemia

Top Venues

BioMed research international

Cancer chemotherapy and pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Chuanying Geng, Guangzhong Yang, Huijuan Wang, Zhiyao Zhang, Huixing Zhou, Wen-Ming Chen
The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma. BioMed research international 2021 (2021)
Zhi-Yao Zhang, Yan-Chen Li, Chuan-Ying Geng, Hui-Juan Wang, Wen-Ming Chen
Potential Relationship between Clinical Significance and Serum Exosomal miRNAs in Patients with Multiple Myeloma. BioMed research international 2019 (2019)
Yue Zhang, Xiao-Lei Chen, Wen-Ming Chen, He-Bing Zhou
Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma. BioMed research international 2019 (2019)
Wenming Chen, Yue Zhang, Wan-Qiu Zhu, Xiao-Lei Chen, He-Bing Zhou, Wen-Ming Chen
Peripheral Blood Lymphocyte-to-Monocyte Ratio as a Useful Prognostic Factor in Newly Diagnosed Multiple Myeloma. BioMed research international 2018 (2018)
Yun Leng, Jian Hou, Jie Jin, Mei Zhang, Xiaoyan Ke, Bin Jiang, Ling Pan, Linhua Yang, Fang Zhou, Jianmin Wang, Zhao Wang, Li Liu, Wei Li, Zhixiang Shen, Lugui Qiu, Naibai Chang, Jianyong Li, Jing Liu, Hongyan Pang, Haitao Meng, Peng Wei, Hua Jiang, Yan Liu, Xiangjun Zheng, Shifang Yang, Wen-Ming Chen
Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study. Cancer chemotherapy and pharmacology 79 (6) (2017)